These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32349864)

  • 1. B-cell prolymphocytic leukaemia with a t(4;14) FGFR3/IGH translocation: response to ibrutinib.
    George P; Brown A; Weinkove R
    Pathology; 2020 Jun; 52(4):491-492. PubMed ID: 32349864
    [No Abstract]   [Full Text] [Related]  

  • 2. Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia.
    Oka S; Ono K; Nohgawa M
    Invest New Drugs; 2020 Oct; 38(5):1598-1600. PubMed ID: 31965420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors.
    Patil N; Went RG
    Br J Haematol; 2019 Aug; 186(4):e80-e82. PubMed ID: 30941750
    [No Abstract]   [Full Text] [Related]  

  • 4. Smudge cells following treatment with pentostatin in a patient with B-cell prolymphocytic leukemia.
    Yun HD; Waller EK
    Blood; 2013 Jul; 122(4):474. PubMed ID: 24049774
    [No Abstract]   [Full Text] [Related]  

  • 5. De novo B-cell prolymphocytic leukemia with central nervous system involvement.
    Tatarczuch M; Blombery P; Seymour JF
    Leuk Lymphoma; 2014 Jul; 55(7):1665-7. PubMed ID: 24047478
    [No Abstract]   [Full Text] [Related]  

  • 6. Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations.
    Damlaj M; Al Balwi M; Al Mugairi AM
    Leuk Lymphoma; 2018 Mar; 59(3):739-742. PubMed ID: 28695755
    [No Abstract]   [Full Text] [Related]  

  • 7. Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.
    Eyre TA; Fox CP; Shankara P; Went R; Schuh AH
    Br J Haematol; 2017 May; 177(3):486-491. PubMed ID: 27061924
    [No Abstract]   [Full Text] [Related]  

  • 8. BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.
    Fiorcari S; Maffei R; Vallerini D; Scarfò L; Barozzi P; Maccaferri M; Potenza L; Ghia P; Luppi M; Marasca R
    Front Immunol; 2020; 11():2158. PubMed ID: 32983178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.
    İskender G; İskender D; Ertek M
    Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674
    [No Abstract]   [Full Text] [Related]  

  • 10. Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
    Ozbagcivan O; Akarsu S; Nazli EC; Lebe B; Fetil E
    Ann Hematol; 2021 Jan; 100(1):293-294. PubMed ID: 32221651
    [No Abstract]   [Full Text] [Related]  

  • 11. B and T cell prolymphocytic leukaemia.
    Cross M; Dearden C
    Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review.
    Metzler JM; Burla L; Fink D; Imesch P
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32532074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapsed B-cell prolymphocytic leukemia (B-PLL) with distinctive granular inclusion bodies.
    Su MY; Chen TC; Teng CJ; Wu CH
    Int J Lab Hematol; 2024 Aug; 46(4):585-586. PubMed ID: 38284307
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.
    Solman IG; Blum LK; Burger JA; Kipps TJ; Dean JP; James DF; Mongan A
    Leuk Res; 2021 Mar; 102():106520. PubMed ID: 33611131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features and diagnosis of hairy cell leukemia.
    Quest GR; Johnston JB
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):180-92. PubMed ID: 26614896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central Nervous System Post-transplant Lymphoproliferative Disorder: Response to Ibrutinib.
    Kallam A; Hansen N; Bierman P
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e930-e933. PubMed ID: 32782203
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful Rapid Oral Desensitization to Ibrutinib in a Patient With Severe Immediate Hypersensitivity Reaction.
    Tsilimidos G; Horisberger A; Ribi C; Cairoli A; Stalder G
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e745-e747. PubMed ID: 34158264
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
    Morabito F; Tripepi G; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Vigna E; Martino EA; Mendicino F; Botta C; Caracciolo D; Cassin R; D'Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Cutrona G; Rossi D; Di Raimondo F; Cuneo A; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
    Am J Hematol; 2021 May; 96(5):E168-E171. PubMed ID: 33580969
    [No Abstract]   [Full Text] [Related]  

  • 19. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
    Molica S; Gianfelici V; Levato L
    Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
    [No Abstract]   [Full Text] [Related]  

  • 20. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.